<DOC>
	<DOCNO>NCT00441961</DOCNO>
	<brief_summary>Evaluate effect high dose MTX skin induration patient eosinophilic fascia .</brief_summary>
	<brief_title>Treatment With High Dose Methotrexate Patients With Eosinophilic Fasciitis</brief_title>
	<detailed_description>Eosinophilic fasciitis ( EF ) fibrosing skin disorder extensively involve deep fascia . The aim pilot study evaluate effect high dose MTX skin induration patient EF . In addition , study effect treatment joint mobility , peripheral blood eosinophilia , functional ability , pulmonary function . By administer high dose MTX intravenously every four week Leukovorin rescue , hope induce pronounced sustained effect involve skin less ( long-lasting ) side effect .</detailed_description>
	<mesh_term>Fasciitis</mesh_term>
	<mesh_term>Eosinophilia</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Eosinophilic fasciitis define clinical judgement expert , Histologically confirm skinfasciamuscle biopsy , additon : Either presence modify skin score accord Zachariae 8 high ( 018 ) , regard generalise eosinophilic fasciitis presence severe contracture due eosinophilic fasciitis lesion . Age &lt; 18 yrs Contraindications MTX : AST/ALT level &gt; 2 time upper limit normal , WBC count &lt; 3.5 x 109/l platelet count &lt; 150 x 109/l , serum creatinine &gt; 130 micromol/l clearance &lt; 50 ml/min , confirm two repeated test within one month . Chronic liver disease , insulin dependant diabetes mellitus , alcohol abuse Restrictive pulmonary disease ( total lung capacity vital capacity &lt; 40 % predict ) interstitial lung disease ( KCO &lt; 60 % predict ) Pregnancy child bear potential without adequate contraception The presence serious comorbidity malignancy Use antifolate drug MTX</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Eosinophilic fasciitis , Shulman 's syndrome , methotrexate</keyword>
</DOC>